PainChek’s CEO transition comes as the growth baton moves to US execution

PainChek’s ASX announcement yesterday was technically about a CEO transition, but the more useful investor read-through is that the company is reshaping itself for a different kind of race.

The company said Philip Daffas will cease as chief executive and managing director, with chief operating officer Andy Hoggan stepping in as interim CEO while the board progresses the search for a permanent replacement. PainChek described the move as a planned transition to support its FY27 strategy following FDA De Novo clearance, with the board and Daffas agreeing that now is the right time for a leadership change to accelerate development of the US market.

That last bit is the nub. CEO departures can leave investors checking under the floorboards for bad news, especially in small-cap medtech. But PainChek has gone out of its way to frame this as succession at an inflection point, not a corporate banana skin. Daffas departs after a decade in which PainChek moved from Australian research origins to what the company says is the world’s first AI-powered, clinically validated pain assessment platform, with operations in Australia, the UK, New Zealand and North America. Under his watch, the company completed more than 20 million clinical assessments, secured contracts with more than 2,000 aged care facilities and achieved US FDA clearance.

That is a fair list of milestones. It also means the incoming CEO does not inherit a blank sheet, or worse, a medtech still wandering the regulatory desert with a half-built product and a PowerPoint full of hockey sticks. PainChek has an established base in its home and offshore markets, with the company understood to have about 30 per cent market share in Australia and about 10 per cent in the UK, both still growing.

The task now is different. PainChek is no longer merely trying to prove that its technology works, or that regulators will allow it into major markets. The challenge is to convert regulatory clearance, reimbursement access, existing market share and early US distribution into scalable recurring revenue.

PainChek’s technology uses artificial intelligence and clinical inputs to assess and monitor pain, particularly in people who cannot reliably self-report, including many people living with dementia. Its app combines an AI pain assessment tool with the Numerical Rating Scale, allowing assessment at the point of care and reporting through PainChek Analytics. The company says the product is regulatory-cleared in Australia, the US, Canada, the European Union, New Zealand, Singapore, Malaysia and the UK.

The most important recent commercial proof point is the Sabra Health Care REIT agreement announced in April. Sabra, a Nasdaq-listed healthcare real estate investment trust, has agreed to fund PainChek across as many as 20,000 beds in 329 skilled nursing, long-term care and senior housing facilities in the US and Canada. The agreed pricing range is US$55 to US$75 per bed per annum.

The significance is not that every Sabra-related bed should be treated as revenue in the bag. That would be getting ahead of the knitting. Rather, the agreement gives PainChek a potentially more efficient route into large senior-care portfolios, with an owner-backed structure that can reduce adoption friction for operators. Daffas described the model as a “blueprint” for PainChek in the US, transferable to other large real estate investment trusts that own long-term care and senior living facilities.

By June, that blueprint had produced its first on-the-ground contracts. PainChek secured two three-year commercial deployments with Traditions memory care facilities under the Sabra master services agreement. The company was careful to say the immediate financial impact was not material, but the announcement provided early evidence that the Sabra arrangement can convert from framework agreement to actual deployment.

Sabra is not the only US door PainChek has been trying to open. The company has also built a broader partnership and integration network intended to make the product easier to adopt inside aged-care workflows, rather than forcing nurses and carers to wrestle with yet another standalone system. Its North American push is supported by strategic partner opportunities and integration pathways that should begin rolling out over coming quarters, complementing direct sales, reimbursement-led programs and channel relationships.

That may sound less glamorous than a headline customer win, but it matters. In aged care, a clinical tool that does not integrate can become one more thing on an already overcrowded clipboard. PainChek’s partner strategy is designed to reduce double handling, support real-time data transfer and embed pain assessment into existing care-management and electronic record systems. For the incoming CEO, this means the US opportunity is not resting solely on one agreement. PainChek has FDA clearance, an initial Sabra-backed deployment pathway, integration infrastructure and strategic relationships that are now moving from preparation to field execution.

The clinical and demographic logic of the US push is also straightforward. PainChek said the skilled nursing and memory care sectors are where its product can have the greatest impact, noting that more than three million US nursing home residents are diagnosed with Alzheimer’s disease and related dementias. Daffas said PainChek is the only FDA-cleared medical device to assess pain for people living with dementia.

The leadership change also follows a notable board refresh. In May, Lil Bianchi was appointed non-executive chair, succeeding John Murray, who moved to a non-executive director role. PainChek highlighted Bianchi’s experience guiding medtech companies through growth inflection points and international expansion, including as chair of 4DMedical and as a non-executive director of Qscan Radiology Group. Her appointment was explicitly linked to PainChek’s US business development drive following FDA De Novo clearance and access to US CMS reimbursement.

Bianchi said at the time she was joining at an “exciting moment” as PainChek looked to accelerate access into the large US market. Murray said the board had searched for someone with proven experience growing medtech businesses internationally, particularly in North America.

Capital has also been lined up for the push. In May, PainChek secured A$5.5 million through unsecured convertible notes from a small group of existing sophisticated and professional investor shareholders. The funds are earmarked for US sales and marketing expansion and general working capital. The notes have a 12-month maturity, a 12 per cent annual interest rate payable monthly, and a fixed conversion price of 19.5 cents. Daffas said the funding came at a pivotal time after the Sabra agreement and access to Remote Therapeutic Monitoring reimbursement.

For investors, the attractions and caveats sit side by side. PainChek has regulatory clearance, a differentiated AI-enabled product, meaningful market positions in Australia and the UK, a large aged-care use case, and a US channel strategy that could scale faster than selling facility by facility. It also has the usual small-cap medtech homework: converting early deployments into recurring revenue, managing cash burn, proving US sales repeatability and ensuring the new CEO can keep momentum rather than spend six months admiring the furniture.

Seen in that light, yesterday’s CEO transition announcement looks less like a sudden change of direction and more like a baton pass. Daffas helped get the product invented, validated, cleared and into thousands of facilities. The next boss will arrive with a real commercial base, early US traction, several partner pathways and a board clearly focused on the next growth phase.

For PainChek, the door to America has been opened. The next test is whether it can stride through with enough contracts, cash discipline and execution muscle to make investors believe the story has finally moved from clinical promise to commercial scale.